{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T18:30:05Z","timestamp":1792002605004,"version":"4.4.0"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,2]],"date-time":"2022-02-02T00:00:00Z","timestamp":1643760000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.ejca.2022.01.017","type":"journal-article","created":{"date-parts":[[2022,2,24]],"date-time":"2022-02-24T08:25:35Z","timestamp":1645691135000},"page":"97-112","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":57,"special_numbering":"C","title":["Prognostic and predictive value of \u03b2-blockers in the EORTC 1325\/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma"],"prefix":"10.1016","volume":"165","author":[{"given":"Oliver J.","family":"Kennedy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michal","family":"Kicinski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Valpione","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Gandini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Suciu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian U.","family":"Blank","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgina V.","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria G.","family":"Atkinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Dalle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew M.","family":"Haydon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrey","family":"Meshcheryakov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adnan","family":"Khattak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo S.","family":"Carlino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahneen","family":"Sandhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Larkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susana","family":"Puig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo A.","family":"Ascierto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Rutkowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Schadendorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rutger","family":"Koornstra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonel","family":"Hernandez-Aya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna M.","family":"Di Giacomo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfonsus J.M.","family":"van den Eertwegh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Jacques","family":"Grob","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralf","family":"Gutzmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahima","family":"Jamal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander C.J.","family":"van Akkooi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Robert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander M.M.","family":"Eggermont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Lorigan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Mandala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2022.01.017_bib1","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1615\/CritRevImmunol.2019031188","article-title":"Beta-adrenergic signaling in tumor immunology and immunotherapy","volume":"39","author":"Wang","year":"2019","journal-title":"Crit Rev Immunol"},{"key":"10.1016\/j.ejca.2022.01.017_bib2","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1158\/1078-0432.CCR-11-0641","article-title":"Molecular pathways: beta-adrenergic signaling in cancer","volume":"18","author":"Cole","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2022.01.017_bib3","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/labinvest.2012.175","article-title":"\u03b2-adrenoceptors are upregulated in human melanoma and their activation releases pro-tumorigenic cytokines and metalloproteases in melanoma cell lines","volume":"93","author":"Moretti","year":"2013","journal-title":"Lab Invest"},{"key":"10.1016\/j.ejca.2022.01.017_bib4","doi-asserted-by":"crossref","first-page":"95","DOI":"10.18632\/oncoscience.357","article-title":"Beta-adrenergic receptors are expressed across diverse cancers","volume":"4","author":"Rains","year":"2017","journal-title":"Oncoscience"},{"key":"10.1016\/j.ejca.2022.01.017_bib5","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.bja.2018.03.024","article-title":"Effect of beta-blockers on cancer recurrence and survival: a meta-analysis of epidemiological and perioperative studies","volume":"121","author":"Yap","year":"2018","journal-title":"Br J Anaesth"},{"key":"10.1016\/j.ejca.2022.01.017_bib6","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1001\/archinternmed.2011.131","article-title":"Treatment with \u03b2-blockers and reduced disease progression in patients with thick melanoma","volume":"171","author":"De Giorgi","year":"2011","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.ejca.2022.01.017_bib7","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1016\/j.mayocp.2013.09.001","article-title":"Effect of \u03b2-blockers and other antihypertensive drugs on the risk of melanoma recurrence and death","volume":"88","author":"De Giorgi","year":"2013","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.ejca.2022.01.017_bib8","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.ejca.2020.02.021","article-title":"Survival of patients with advanced metastatic melanoma: the impact of MAP kinase pathway inhibition and immune checkpoint inhibition - update 2019","volume":"130","author":"Ugurel","year":"2020","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2022.01.017_bib9","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1056\/NEJMoa1802357","article-title":"Adjuvant pembrolizumab versus placebo in resected stage III melanoma","volume":"378","author":"Eggermont","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2022.01.017_bib10","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1200\/JCO.20.02110","article-title":"Longer follow-up confirms recurrence-free survival benefit of adjuvant pembrolizumab in high-risk stage III melanoma: updated results from the EORTC 1325-MG\/KEYNOTE-054 trial","volume":"38","author":"Eggermont","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2022.01.017_bib11","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/S1470-2045(21)00065-6","article-title":"Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG\/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial","volume":"22","author":"Eggermont","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2022.01.017_bib12","doi-asserted-by":"crossref","first-page":"5639","DOI":"10.1158\/0008-5472.CAN-17-0546","article-title":"\u03b2-Adrenergic signaling in mice housed at standard temperatures suppresses an effector phenotype in CD8(+) T cells and undermines checkpoint inhibitor therapy","volume":"77","author":"Bucsek","year":"2017","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2022.01.017_bib13","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1405205","article-title":"Beta blocker use correlates with better overall survival in metastatic melanoma patients and improves the efficacy of immunotherapies in mice","volume":"7","author":"Kokolus","year":"2018","journal-title":"OncoImmunology"},{"key":"10.1016\/j.ejca.2022.01.017_bib14","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1093\/biomet\/80.3.557","article-title":"Checking the Cox model with cumulative sums of martingale-based residuals","volume":"80","author":"Lin","year":"1993","journal-title":"Biometrika"},{"key":"10.1016\/j.ejca.2022.01.017_bib15","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/clpt.1989.161","article-title":"A new method for isolation of human lymphocyte subsets reveals differential regulation of beta-adrenergic receptors by terbutaline treatment","volume":"46","author":"Maisel","year":"1989","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.ejca.2022.01.017_bib16","doi-asserted-by":"crossref","first-page":"4200","DOI":"10.4049\/jimmunol.158.9.4200","article-title":"Differential expression of the beta2-adrenergic receptor by Th1 and Th2 clones: implications for cytokine production and B cell help","volume":"158","author":"Sanders","year":"1997","journal-title":"J Immunol"},{"key":"10.1016\/j.ejca.2022.01.017_bib17","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1158\/1055-9965.EPI-11-0249","article-title":"\u03b2-Blockers and survival among Danish patients with malignant melanoma: a population-based cohort study","volume":"20","author":"Lemeshow","year":"2011","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.ejca.2022.01.017_bib18","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1111\/bjd.12894","article-title":"Beta-blocker usage after malignant melanoma diagnosis and survival: a population-based nested case-control study","volume":"170","author":"McCourt","year":"2014","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ejca.2022.01.017_bib19","doi-asserted-by":"crossref","first-page":"3863","DOI":"10.1016\/j.ejca.2013.07.141","article-title":"\u03b2-Blocker use and all-cause mortality of melanoma patients: results from a population-based Dutch cohort study","volume":"49","author":"Livingstone","year":"2013","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2022.01.017_bib20","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12113228","article-title":"The effect of beta-adrenergic blocking agents in cutaneous melanoma-A nation-wide Swedish population-based retrospective register study","volume":"12","author":"Katsarelias","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.ejca.2022.01.017_bib21","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2017.2908","article-title":"Propranolol for off-label treatment of patients with melanoma: results from a cohort study","volume":"4","author":"De Giorgi","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ejca.2022.01.017_bib22","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/S1470-2045(18)30077-9","article-title":"BMI and outcomes in melanoma: more evidence for the obesity paradox","volume":"19","author":"Hayes","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2022.01.017_bib23","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12051230","article-title":"The effects of obesity on anti-cancer immunity and cancer immunotherapy","volume":"12","author":"Woodall","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.ejca.2022.01.017_bib24","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/S1470-2045(18)30078-0","article-title":"Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis","volume":"19","author":"McQuade","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2022.01.017_bib25","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001117","article-title":"Body mass index (BMI) and outcome of metastatic melanoma patients receiving targeted therapy and immunotherapy: a multicenter international retrospective study","volume":"8","author":"Rutkowski","year":"2020","journal-title":"J Immunother Cancer"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804922000387?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804922000387?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:35:28Z","timestamp":1760733328000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804922000387"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":25,"alternative-id":["S0959804922000387"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2022.01.017","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prognostic and predictive value of \u03b2-blockers in the EORTC 1325\/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2022.01.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}